292 related articles for article (PubMed ID: 25098458)
1. [The switch of enzyme therapy in Fabry disease].
Riccio E; Pisani A
G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098458
[TBL] [Abstract][Full Text] [Related]
2. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
4. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
5. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
7. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
[TBL] [Abstract][Full Text] [Related]
8. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
10. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
11. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
13. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
[TBL] [Abstract][Full Text] [Related]
14. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
[TBL] [Abstract][Full Text] [Related]
15. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
16. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
[TBL] [Abstract][Full Text] [Related]
17. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
18. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
Pisani A; Riccio E; Sabbatini M
Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
[No Abstract] [Full Text] [Related]
19. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
20. [Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies].
Pisani A; Visciano B; Capuano I; Mancini A; Riccio E
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
